Neuronal expression of familial Parkinson's disease A53T α-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice

Journal of Parkinson's Disease

Volumn 3, Issue 2, 2013, Pages 215-229

  Rothman, Sarah M ^a   Griffioen, Kathleen J ^a   Vranis, Neil ^a   Ladenheim, Bruce ^b   Cong, Wei Na ^a   Cadet, Jean Lud ^b   Haran, Jamie ^a   Martin, Bronwen ^a   Mattson, Mark P ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

synuclein; anxiety; circadian; dopamine; hypothalamus; Parkinson's disease; serotonin; sleep; stride length

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE TRANSPORTER; SEROTONIN; THY 1 ANTIGEN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOTHALAMUS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; ROTAROD TEST; SIGNAL TRANSDUCTION; SLEEP DISORDER; SLEEP TIME; SURGICAL TECHNIQUE;

AGE FACTORS; ANIMALS; ANXIETY; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MAZE LEARNING; MICE; MICE, TRANSGENIC; MUTATION; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; SLEEP DISORDERS; TYROSINE 3-MONOOXYGENASE;

EID: 84880232532     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-120130     Document Type: Article

References (49)

1. Gallagher DA, & Schrag A (2012) Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis, 46, 581-589.
2. Rothman SM, & Mattson MP (2012) Sleep disturbances in Alzheimer's and Parkinson's diseases. Neuromol Med, 14, 194-204.
3. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, & Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA, 95, 6469-6473.
4. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, & Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
5. Crabtree DM, & Zhang J (2012) Genetically engineered mouse models of Parkinson's disease. Brain Res Bull, 88, 13-32.
6. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, SagaraY, Sisk A,&Mucke L (2000) Dopaminergic loss and inclusion body formation in alphasynuclein mice: Implications for neurodegenerative disorders. Science, 287, 1265-1269.
7. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, & Masliah E (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res, 68, 568-578.
8. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-Clement J, Korf HW, Deller T, Braak H, Auburger G, & Nussbaum RL (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci, 24, 419-429.
9. Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, & Chesselet MF (2008) Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci, 28, 247-256.
10. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, & Chesselet MF (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci, 24, 9434-9440.
11. Gallardo G, Schl̈uter OM, & S̈udhof TC (2008) A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci, 11, 301-308.
12. Zhou W, & Freed CR (2004) Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity. J Biol Chem, 279, 10128-10135.
13. Chandra S, Gallardo G, Ferńandez-Chaćon R, Schl̈uter OM, &S̈udhof TC (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell, 123, 383-396.
14. Griffioen KJ, Rothman SM, Ladenheim B, Wan R, Vranis N, Hutchison E, Okun E, Cadet JL, & Mattson MP (2013) Dietary energy intake modifies brainstem autonomic dysfunction caused by mutant-synuclein. Neurobiol Aging, 34, 928-935.
15. Fernagut PO, Diguet E, Labattu B, & Tison FA (2002) A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Meth, 113, 123-130.
16. Bessa JM, Oliveira M, Cerqueira JJ, Almeida OF, & Sousa N (2005) Age-related qualitative shift in emotional behaviour: Paradoxical findings after re-exposure of rats in the elevatedplus maze. Behav Brain Res, 162, 135-142.
17. Pack AI, Galante RJ, Maislin G, Cater J, Metaxas D, Lu S, Zhang L, Von Smith R, Kay T, Lian J, Svenson K, & Peters LL (2007) Novel method for high-throughput phenotyping of sleep in mice. Physiol Genomics, 28, 232-238.
18. Jakes R, Crowther RA, Lee VM, Trojanowski JQ, Iwatsubo T, & Goedert M (1999) Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett, 269, 13-16.
19. Kokkotou E, Jeon JY, Wang X, Marino FE, Carlson M, Trombly DJ, & Maratos-Flier E (2005) Mice with MCH ablation resist diet-induced obesity through strain-specific mechanisms. Am J Physiol Regul Integr Comp Physiol, 289, R117-R124.
20. Belzung C,&Griebel G (2001) Measuring normal and pathological anxiety-like behaviour in mice:Areview. Behav Brain Res, 125, 141-149.
21. Schneider P, Ho YJ, Spanagel R,&PawlakCR(2011)Anovel elevated plus-maze procedure to avoid the one-trial tolerance problem. Front Behav Neurosci, 5, 43.
22. Afonso-Oramas D, Cruz-Muros I, Barroso-Chinea P, Á lvarez de la Rosa D, Castro-Herńandez J, Salas-Herńandez J, Giŕaldez T, & Gonźalez-Herńandez T (2010) The dopamine transporter is differentially regulated after dopaminergic lesion. Neurobiol Dis, 40, 518-530.
23. George S, van den Buuse M, San Mok S, Masters CL, Li QX, & Culvenor JG (2008) Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp Neurol, 210, 788-792.
24. Salvatore MF, Apparsundaram S, & Gerhardt GA (2003) Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol Aging, 24, 1147-1154.
25. Yue F, Zeng S, Wu D, Yi D, Alex Zhang Y, & Chan P (2012) Age-related decline in motor behavior and striatal dopamine transporter in cynomolgus monkeys. J Neural Transm, 119, 943-952.
26. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ,& Lee VM (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alphasynuclein. Neuron, 34, 521-533.
27. Cummings JL (1992) Depression and Parkinson's disease: A review. Am J Psychiat, 149, 443-454.
28. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, & Martens MP (2001) Prevalence, Clinical Manifestations, Etiology, and Treatment of Depression in Parkinson's Disease. J Neuropsychiat Clin Neurosci, 13, 187-196.
29. Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, Iuvone PM, Weinshenker D, Greene JG, & Miller GW (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci, 29, 8103-8113.
30. Graham DR, & Sidhu A (2010) Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res, 88, 1777-1783.
31. Blonder LX, & Slevin JT (2011) Emotional dysfunction in Parkinson's disease. Behav Neurol, 24, 201-217.
32. Weintraub D, & Burn DJ (2011) Parkinson's disease: The quintessential neuropsychiatric disorder. Mov Disord, 26, 1022-1031.
33. Bugalho P, da Silva JA, Cargaleiro I, Serra M, & Neto B (2012) Psychiatric symptoms screening in the early stages of Parkinson's disease. J Neurol, 259, 124-131.
34. Yamakado H, Moriwaki Y, Yamasaki N, Miyakawa T, Kurisu J, Uemura K, Inoue H, Takahashi M, & Takahashi R (2012) Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion. Neurosci Res, 73, 173-177.
35. Chu Y, & Kordower JH (2007) Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis, 25, 134-149.
36. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, Baudrexel S, Diederich NJ, Heiss WD, & Hilker R (2010) Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology, 74, 885-892.
37. Cervenka S, Hedman E, Ikoma Y, Djurfeldt DR, R̈uck C, Halldin C, Lindefors N (2012) Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder. Transl Psychiat, 2, e120.
38. Lin X, Parisiadou L, Sgobio C, Liu G, Yu J, Sun L, Shim H, Gu XL, Luo J, Long CX, Ding J, Mateo Y, Sullivan PH, Wu LG, Goldstein DS, Lovinger D, & Cai H (2012) Conditional expression of Parkinson's disease-related mutant-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci, 32, 9248-9264.
39. Belin AC, Westerlund M, Anvret A, Lindqvist E, Pernold K, Ogren SO, Duester G, & Galter D (2011) Modeling Parkinson's disease genetics: Altered function of the dopamine system in Adh4 knockout mice. Behav Brain Res, 217, 439-445.
40. Giros B, Jaber M, Jones SR, Wightman RM, & Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 379, 606-612.
41. Carpenter AC, Saborido TP, & Stanwood GD (2012) Development of hyperactivity and anxiety responses in dopamine transporter-deficient mice. Dev Neurosci, 34, 250-257.
42. Maron E, Nutt D,&Shlik J (2012) Neuroimaging of serotonin system in anxiety disorders. Curr Pharm Des, 18, 5699-5708.
43. Wersinger C, Jeannotte A, & Sidhu A (2006) Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein. Eur J Neurosci, 24, 3141-3152.
44. File SE, Mabbutt PS,&Hitchcott PK (1990) Characterisation of the phenomenon of "one-trial tolerance" to the anxi olytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology (Berl), 102, 98-101.
45. Kudo T, Loh DH, Truong D, Wu Y, & Colwell CS (2011) Circadian dysfunction in a mouse model of Parkinson's disease. Exp Neurol, 232, 66-75.
46. Gingrich JA (2002) Mutational analysis of the serotonergic system: Recent findings using knockout mice. Curr Drug Targets CNS Neurol Disord, 1, 449-465.
47. McMorris T, Harris RC, Swain J, Corbett J, Collard K, Dyson RJ, Dye L, Hodgson C, & Draper N (2006) Effect of creatine supplementation and sleep deprivation, with mild exercise, on cognitive and psychomotor performance, mood state, and plasma concentrations of catecholamines and cortisol. Psychopharmacology (Berl), 185, 93-103.
48. Nakamaru-Ogiso E, Miyamoto H, Hamada K, Tsukada K, & Takai K (2012) Novel biochemical manipulation of brain serotonin reveals a role of serotonin in the circadian rhythm of sleep-wake cycles. Eur J Neurosci, 35, 1762-1770.
49. Monti JM (2011) Serotonin control of sleep-wake behavior. Sleep Med Rev, 15, 269-281.